Is Lipocine Inc (LPCN) overvalued? · rev $11.2M
Lipocine Inc (LPCN) is a biotechnology company listed on NASDAQ.
This page asks whether Lipocine Inc (LPCN) looks expensive on cached numbers — not a short thesis.
Latest reported LPCN revenue for 2024-12-31 was $11.2M. Net income was $8.4K. Revenue was up 492.8% from 2023-12-31 to 2024-12-31. LPCN currently screens at market cap $19.3M.
LPCN currently screens at market cap $19.3M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next LPCN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the LPCN stock page for the full model, not this heading.
Not investment advice.